#USA #Chicago #Neurelis #VALTOCO #AAN Meeting

Neurelis to Present Findings on Diazepam Nasal Spray at AAN Annual Meeting

Neurelis, Inc. is gearing up to share its latest insights into immediate-use seizure treatments at the upcoming American Academy of Neurology (AAN) Annual Meeting, scheduled from April 18-22, 2026, in Chicago. As the company focuses on improving epilepsy care, two key poster presentations will be made, highlighting significant findings regarding the use of diazepam nasal spray in prehospital settings.

Highlights of the Presentations

The first presentation will delve into a post-hoc analysis derived from long-term safety studies evaluating the efficacy of diazepam nasal spray for treating status epilepticus (SE) within seizure clusters. This analysis pools data from two distinct studies—one involving adult patients aged 6-65 years and another focused on pediatric patients aged 2-5 years. By addressing both generalized and focal seizures, the study aims to underscore the critical role of diazepam nasal spray as an immediate-use seizure medication (ISM).

Dr. Adrian L. Rabinowicz, MD, Chief Medical Officer of Neurelis, expressed his enthusiasm about participating in the AAN Annual Meeting. He emphasized the importance of engaging with the neurology community—clinicians, researchers, and patients—to share insights and ongoing developments in epilepsy treatment. In line with Neurelis' mission, the analysis will showcase how timely intervention with diazepam nasal spray contributes to effective seizure termination and less frequent hospitalization due to SE episodes.

The second presentation will compare healthcare resource utilization (HCRU) between patients with epilepsy (PWE) who use diazepam nasal spray and those who do not. By leveraging a comprehensive U.S. claims database of 300 million patients, the retrospective study will highlight the differences in healthcare usage, demonstrating that patients who are prescribed diazepam nasal spray experience significantly fewer inpatient and outpatient visits. Furthermore, the data illustrates a lower readmission rate among those utilizing this immediate-use treatment, making a compelling case for the clinical benefits of diazepam nasal spray in managing seizure clusters.

Enhancing Treatment of Epilepsy

Neurelis is committed to addressing the pressing needs faced by individuals living with epilepsy. The ongoing research and insights shared at the AAN Annual Meeting align with the company's vision to enhance the quality of life for patients battling this condition. The promising results from their studies not only emphasize the importance of timely treatment but also the potential to reduce the overall healthcare burden associated with epilepsy treatment.

The focus on diazepam nasal spray comes at a pivotal moment when the neurology field recognizes the growing necessity for effective episodic treatments for seizures. By elucidating the advantages of this ISM, Neurelis aims to inform and inspire further innovation in the management of epilepsy—a disorder that impacts millions of individuals and families worldwide.

With the American Academy of Neurology's deep commitment to advancing treatments for brain disorders, Neurelis anticipates that discussions generated from these presentations will foster collaborations and accelerate advancements in epilepsy therapies. As the landscape of epilepsy management continues to evolve, the insights shared at the AAN are expected to play a crucial role in shaping future treatment paradigms.

In conclusion, Neurelis' presentations at the AAN Annual Meeting represent a significant step towards redefining how immediate-use treatments can transform patient care routines in epilepsy, potentially leading to improved healthcare outcomes and better quality of life for those affected by seizure disorders.